Item 8.01 Other Events.
On November 29, 2021, Sigilon Therapeutics, Inc. (the "Company") provided an
update on the Company's Phase 1/2 clinical trial of SIG-001 in hemophilia A,
which is on clinical hold. The Company issued a press release reporting that
fibrosed spheres were observed during a retrieval procedure in a patient dosed
in the study, which is filed as Exhibit 99.1 to this Current Report on Form 8-K,
and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
Press Release Issued by Sigilon Therapeutics, Inc. on November 29,
99.1 2021
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document)
© Edgar Online, source Glimpses